Denzimol is a novel anticonvulsant compound.Denzimol is selective for tonic seizures.

Denzimol (30 mg/kg; p.o.; 14 days; mice) reduced brain concentration and anticonvulsant activity compared with non-treated mice, and t1/2 beta was significantly changed from 2.10 to 1.53 hr. Tonic hindlimb extension was completely abolished at a brain denzimol concentration higher than 15 mcg/g, whereas the minimum effective brain concentration was between 2-3 mcg/g both in acute and repeatedly treated animals. The brain concentration of denzimol is closely correlated with its anticonvulsant effect both in acute and repeatedly treated animals. Furthermore, these findings seem to suggest that the decreased anticonvulsant activity of denzimol, following repeated administrations, might be due to a development of pharmacokinetic tolerance.[4]